You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
CareDx first sued Natera in March 2019 for infringing two of its patents, then amended the suit a year later to add a third patent.
The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.
Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 firms' share prices decreased.
The company reported $53.4 million in total revenues for the quarter and said testing services revenues rose 61 percent year over year.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The company said it provided approximately 21,800 total AlloSure and AlloMap patient results during the quarter.
CareDx hopes the final LCD for AlloSure Heart will lead to an approval of HeartCare, a combination of AlloSure Heart and AlloMap Heart.
The company reported $41.8 million in total revenues for the quarter and said testing services revenues rose 41 percent year over year.
Of the 28 companies in the index, 22 firms saw their stock prices increase, while six firms' share prices decreased.
The investment bank said CareDx's products are gaining traction and that the stock is positioned for 20 percent to 30 percent growth over the next few years.